Literature DB >> 18555644

An analysis of medicare payment policy for total joint arthroplasty.

Kevin J Bozic1, Harry E Rubash, Thomas P Sculco, Daniel J Berry.   

Abstract

Medicare facility payment policy for lower extremity total joint arthroplasty (TJA) has undergone extensive changes since 2005. The purpose of this study was to compare patient and procedure characteristics and resource use among TJA procedures and to identify predictors of resource use in TJA. Clinical, demographic, and economic data were analyzed from 6483 primary or revision TJA patients from 4 high-volume centers between October 2005 and June 2006. Descriptive analyses were conducted to evaluate differences between procedure types, and multivariable linear regression analyses were undertaken to identify predictors of resource use. Both patient severity of illness and surgical complexity influenced resource use associated with TJA procedures. As the primary goal of Medicare payment policy is to set payment rates proportional to relative resource use, both severity of illness and surgical complexity should be incorporated for payment equity and to minimize incentives for selection bias among hospitals that perform TJA procedures.

Entities:  

Mesh:

Year:  2008        PMID: 18555644     DOI: 10.1016/j.arth.2008.04.013

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  16 in total

1.  Is minimally invasive total knee arthroplasty associated with lower costs than traditional TKA?

Authors:  Jason C King; Paul A Manner; Daniel L Stamper; Douglas C Schaad; Seth S Leopold
Journal:  Clin Orthop Relat Res       Date:  2010-12-16       Impact factor: 4.176

Review 2.  Current Trends in Discharge Disposition and Post-discharge Care After Total Joint Arthroplasty.

Authors:  T David Tarity; Marion M Swall
Journal:  Curr Rev Musculoskelet Med       Date:  2017-09

3.  Routine surveillance of modular PFC TKA shows increasing failures after 10 years.

Authors:  Andrew S Malin; John J Callaghan; Kevin J Bozic; Steve S Liu; Devon D Goetz; Nicholas Sullivan; Scott S Kelley
Journal:  Clin Orthop Relat Res       Date:  2010-03-19       Impact factor: 4.176

4.  Treatment of early postoperative infections after THA: a decision analysis.

Authors:  Hany Bedair; Nicholas Ting; Kevin J Bozic; Craig J Della Valle; Scott M Sporer
Journal:  Clin Orthop Relat Res       Date:  2011-10-14       Impact factor: 4.176

5.  Demographic and comorbid disparities based on payer type in a total joint arthroplasty cohort: implications in a changing health care arena.

Authors:  Lucian C Warth; John J Callaghan; Christopher W Wells; Steve S Liu; Alison Klaassen; Yubo Gao; Richard C Johnston
Journal:  Iowa Orthop J       Date:  2011

6.  Prediction Models for 30-Day Mortality and Complications After Total Knee and Hip Arthroplasties for Veteran Health Administration Patients With Osteoarthritis.

Authors:  Alex Hs Harris; Alfred C Kuo; Thomas Bowe; Shalini Gupta; David Nordin; Nicholas J Giori
Journal:  J Arthroplasty       Date:  2017-12-13       Impact factor: 4.757

7.  Readmission rates in the state of Florida: a reflection of quality?

Authors:  Carlos J Lavernia; Jesus M Villa; David A Iacobelli
Journal:  Clin Orthop Relat Res       Date:  2013-12       Impact factor: 4.176

8.  Do the potential benefits of metal-on-metal hip resurfacing justify the increased cost and risk of complications?

Authors:  Kevin J Bozic; Christine M Pui; Matthew J Ludeman; Thomas P Vail; Marc D Silverstein
Journal:  Clin Orthop Relat Res       Date:  2010-09       Impact factor: 4.176

9.  Comorbidities in patients undergoing total knee arthroplasty: do they influence hospital costs and length of stay?

Authors:  Andrew J Pugely; Christopher T Martin; Yubo Gao; Daniel A Belatti; John J Callaghan
Journal:  Clin Orthop Relat Res       Date:  2014-09-05       Impact factor: 4.176

10.  Variation of Medicare payments for total knee arthroplasty.

Authors:  Yue Li; Xin Lu; Brian R Wolf; John J Callaghan; Peter Cram
Journal:  J Arthroplasty       Date:  2013-07-08       Impact factor: 4.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.